Therefore, the identification of NOTCH3 signaling as a mediator of RANKL and bone resorption in the tumor microenvironment suggests the potential use of anti-NOTCH3 antibodies as a therapeutic approach to halting bone destruction in the cancer setting. Here, NOTCH3 is linked to cancer.